This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wadler, S. Articles by Schwartz, E. L. Search for Related Content PubMed PubMed Citation Articles by Wadler, S. Articles by Schwartz, E. L.

Antineoplastic Activity of the Combination of Interferon and Cytotoxic Agents against Experimental and Human Malignancies: A Review¹

Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York 10467

The combination of Interferon (IFN) and conventional chemotherapeutic agents offers a promising therapeutic approach for the treatment of cancer. However, there is as yet no consensus on optimal strategies for combining this family of compounds with other cancer therapies. While in vitro studies have demonstrated both direct cytotoxic and cytokinetic effects for IFN, a more interesting role derives from its ability to synergistically potentiate the activity of a wide variety of cytotoxic agents against multiple human and rodent tumors, both in vitro and in animal models. The interaction between IFN and cytotoxic agents in vitro is complex and depends not only on the choice of cytotoxic agent but also on the concentrations, ratios, duration, and sequence of exposure to the two drugs. Preliminary data suggest that some combinations are not merely additive but rather that IFN may biochemically modulate the cellular uptake or metabolism of the cytotoxic agent resulting in synergistic antineoplastic activity. In vivo interactions between IFN and cytotoxic agents involve an additional layer of complexity because of the potential effects of the biological agent on the host immune system and drug-metabolizing enzymes. Furthermore, IFN may have a protective effect on normal host tissues which theoretically could allow for the delivery of higher doses of cytotoxic agents. The results of early clinical trials using combinations of IFN with chemotherapeutic agents have generally been disappointing. This may be due to the inability of preclinical models to accurately predict the clinical situation or alternatively from a failure to incorporate information on dose, scheduling, and sequence of drug administration into clinical trials. Preliminary clinical studies with IFN- and the fluorinated pyrimidine, 5-fluorouracil, in patients with advanced colorectal carcinoma suggest that IFN may enhance the effects of the antimetabolite. Confirmatory trials are in progress. Further trials designed to exploit the preclinical experience with combinations of IFN and cytotoxic agents are warranted.

¹ Supported in part by American Cancer Society Research Grant CH-479, by Cancer Center Core Grant P30CA13330-16 awarded by the National Cancer Institute, and by a grant from the Mathers Foundation.

² Recipient of a Career Development Award from the American Cancer Society. To whom requests for reprints should be addressed, at Department of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467.

Received 11/ 7/79. Revised 2/ 2/90.

This article has been cited by other articles:

				M. Parton, M. Gore, and T. Eisen Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592. [Abstract] [Full Text] [PDF]

				Q.-H. Sun, J.-P. Peng, and H.-F. Xia IFN{gamma} pretreatment sensitizes human choriocarcinoma cells to etoposide-induced apoptosis Mol. Hum. Reprod., February 1, 2006; 12(2): 99 - 105. [Abstract] [Full Text] [PDF]

				M. A. Bausero, R. Gastpar, G. Multhoff, and A. Asea Alternative Mechanism by which IFN-{gamma} Enhances Tumor Recognition: Active Release of Heat Shock Protein 72 J. Immunol., September 1, 2005; 175(5): 2900 - 2912. [Abstract] [Full Text] [PDF]

				M. Kondo, H. Nagano, H. Wada, B. Damdinsuren, H. Yamamoto, N. Hiraoka, H. Eguchi, A. Miyamoto, T. Yamamoto, H. Ota, et al. Combination of IFN-{alpha} and 5-Fluorouracil Induces Apoptosis through IFN-{alpha}/{beta} Receptor in Human Hepatocellular Carcinoma Cells Clin. Cancer Res., February 1, 2005; 11(3): 1277 - 1286. [Abstract] [Full Text] [PDF]

				U. Chatterji, J. E. Riby, T. Taniguchi, E. L. Bjeldanes, L. F. Bjeldanes, and G. L. Firestone Indole-3-carbinol stimulates transcription of the interferon gamma receptor 1 gene and augments interferon responsiveness in human breast cancer cells Carcinogenesis, July 1, 2004; 25(7): 1119 - 1128. [Abstract] [Full Text] [PDF]

				Y. Hoshiya, V. Gupta, H. Kawakubo, E. Brachtel, J. L. Carey, L. Sasur, A. Scott, P. K. Donahoe, and S. Maheswaran Mullerian Inhibiting Substance Promotes Interferon {gamma}-induced Gene Expression and Apoptosis in Breast Cancer Cells J. Biol. Chem., December 19, 2003; 278(51): 51703 - 51712. [Abstract] [Full Text] [PDF]

				Y. Honma, Y. Ishii, Y. Yamamoto-Yamaguchi, T. Sassa, and K.-i. Asahi Cotylenin A, a Differentiation-inducing Agent, and IFN-{alpha} Cooperatively Induce Apoptosis and Have an Antitumor Effect on Human Non-Small Cell Lung Carcinoma Cells in Nude Mice Cancer Res., July 1, 2003; 63(13): 3659 - 3666. [Abstract] [Full Text] [PDF]

				C. Gennatas, C. Dardoufas, D. Mouratidou, N. Tsavaris, A. Pouli, G. Androulakis, M. Philippakis, D. Voros, T. Batalis, S. Besbeas, et al. Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-{alpha}2b Ann. Onc., March 1, 2003; 14(3): 378 - 382. [Abstract] [Full Text] [PDF]

				D. M. Shin, B. S. Glisson, F. R. Khuri, J. L. Clifford, G. Clayman, S. E. Benner, A. A. Forastiere, L. Ginsberg, D. Liu, J. J. Lee, et al. Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer J. Clin. Oncol., January 15, 2002; 20(2): 364 - 370. [Abstract] [Full Text] [PDF]

				D. M. Shin, F. R. Khuri, B. Murphy, A. S. Garden, G. Clayman, M. Francisco, D. Liu, B. S. Glisson, L. Ginsberg, V. Papadimitrakopoulou, et al. Combined Interferon-Alfa, 13-cis-Retinoic Acid, and Alpha-Tocopherol in Locally Advanced Head and Neck Squamous Cell Carcinoma: Novel Bioadjuvant Phase II Trial J. Clin. Oncol., June 15, 2001; 19(12): 3010 - 3017. [Abstract] [Full Text] [PDF]

				P. J. O'Dwyer, J. Manola, F. H. Valone, L. M. Ryan, J. D. Hines, S. Wadler, D. G. Haller, S. G. Arbuck, L. M. Weiner, R. J. Mayer, et al. Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N -Phosphonoacetyl- l -Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule--An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study J. Clin. Oncol., May 1, 2001; 19(9): 2413 - 2421. [Abstract] [Full Text] [PDF]

				C. Ruiz-Ruiz, C. Muñoz-Pinedo, and A. López-Rivas Interferon-{{gamma}} Treatment Elevates Caspase-8 Expression and Sensitizes Human Breast Tumor Cells to a Death Receptor-induced Mitochondria-operated Apoptotic Program Cancer Res., October 1, 2000; 60(20): 5673 - 5680. [Abstract] [Full Text]

				T. A. Davis, D. G. Maloney, A. J. Grillo-López, C. A. White, M. E. Williams, G. J. Weiner, S. Dowden, and R. Levy Combination Immunotherapy of Relapsed or Refractory Low-Grade or Follicular Non-Hodgkin's Lymphoma with Rituximab and Interferon-{{alpha}}-2a Clin. Cancer Res., July 1, 2000; 6(7): 2644 - 2652. [Abstract] [Full Text]

				H. Eguchi, H. Nagano, H. Yamamoto, A. Miyamoto, M. Kondo, K. Dono, S. Nakamori, K. Umeshita, M. Sakon, and M. Monden Augmentation of Antitumor Activity of 5-Fluorouracil by Interferon {{alpha}} Is Associated with Up-Regulation of p27Kip1 in Human Hepatocellular Carcinoma Cells Clin. Cancer Res., July 1, 2000; 6(7): 2881 - 2890. [Abstract] [Full Text]

				M. Metintas, N. Ozdemir, I. Ucgun, O. Elbek, M. Kolsuz, S. Mutlu, and S. Metintas Cisplatin, Mitomycin, and Interferon-{alpha}2a Combination Chemoimmunotherapy in the Treatment of Diffuse Malignant Pleural Mesothelioma Chest, August 1, 1999; 116(2): 391 - 398. [Abstract] [Full Text] [PDF]

				X.-Q. Qin, N. Tao, A. Dergay, P. Moy, S. Fawell, A. Davis, J. M. Wilson, and J. Barsoum Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice PNAS, November 24, 1998; 95(24): 14411 - 14416. [Abstract] [Full Text] [PDF]

				S. Wadler and E. L. Schwartz New Advances in Interferon Therapy of Cancer Oncologist, August 1, 1997; 2(4): 254 - 267. [Abstract] [Full Text] [PDF]

				P. Solal-Celigny, E. Lepage, N. Brousse, F. Reyes, C. Haioun, M. Leporrier, M. Peuchmaur, A. Bosly, Y. Parlier, P. Brice, et al. Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular Lymphoma N. Engl. J. Med., November 25, 1993; 329(22): 1608 - 1614. [Abstract] [Full Text]

				N. Varela, C. Munoz-Pinedo, C. Ruiz-Ruiz, G. Robledo, M. Pedroso, and A. Lopez-Rivas Interferon-gamma Sensitizes Human Myeloid Leukemia Cells to Death Receptor-mediated Apoptosis by a Pleiotropic Mechanism J. Biol. Chem., May 18, 2001; 276(21): 17779 - 17787. [Abstract] [Full Text] [PDF]